Efficacy and Safety of Oral Antihistamines for Allergic Rhinitis: Network Meta-Analysis
The Journal of Allergy and Clinical Immunology: In Practice · 2026
DOI: 10.1016/j.jaip.2025.12.034 ↗Kurz gefasst
Netzwerk-Metaanalyse in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2026. Verfasst von Rafael José Vieira und 38 weiteren Autor:innen. Beteiligte Einrichtung: MEDCIDS, Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal; CINTE…. Hauptthemen laut MEDLINE: Rhinitis, Allergic, Histamine H1 Antagonists, Rhinitis, Allergic, Seasonal. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Oral H1-antihistamines (OAHs) are among the most frequently used medications for the treatment of allergic rhinitis (AR). OBJECTIVE: To perform a systematic review and network meta-analysis comparing the efficacy and safety of individual OAHs in patients with AR. METHODS: We searched 4 electronic bibliographic databases and 3 clinical trial databases for randomized controlled trials assessing adults with perennial or seasonal AR, and comparing (1) OAH versus placebo or (2) different individual OAHs. We performed a network meta-analysis on the Total Nasal Symptom Score, Total Ocular Symptom Score, Rhinoconjunctivitis Quality-of-Life Questionnaire, development of adverse events, and withdrawals due to adverse events. Certainty of evidence for comparisons involving the most clinically relevant second-generation OAHs was assessed using Grading of Recommendations, Assessment and Evaluation approach to network meta-analysis. RESULTS: We included 74 randomized controlled trials (21 on perennial AR and 53 on seasonal AR). Cetirizine, ebastine, bilastine, and rupatadine were among the individual medications associated with the highest efficacy for improving nasal symptoms. For other efficacy outcomes, the most efficacious interventions varied. A similar frequency of adverse events was observed among different individual second-generation OAHs, with serious adverse events being rare. For most comparisons, the certainty of evidence was rated as "low" or "very low," indicating substantial uncertainty regarding the treatment effects. CONCLUSIONS: Although some OAHs seem to be more efficacious than others, most of the differences between individual second-generation medications are trivial or small. In addition, we did not find any relevant differences in the safety profiles of second-generation OAHs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- MEDCIDS, Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal; CINTESIS@RISE, Health Research Network, MEDCIDS, Faculty of Medicine, Unive…
- CINTESIS@RISE, Health Research Network, MEDCIDS, Faculty of Medicine, University of Porto, Porto, Portugal; Unit of Anatomy, Department of Biomedicine, Faculty of Medicine, University of Porto, Porto, Portugal; Departme…
- CINTESIS@RISE, Health Research Network, MEDCIDS, Faculty of Medicine, University of Porto, Porto, Portugal; Health Research Institute of the Balearic Islands, Palma de Mallorca, Spain.
- Clinical Epidemiology and Research Center (CERC), Humanitas University and Humanitas Research Hospital, Milan, Italy; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, C…
- Evidence Prime, Hamilton, Ontario, Canada.
- Department of Primary Care and Population Health, University of Nicosia Medical School, Nicosia, Cyprus.
Zitieren
APA
Vieira, R. J., Gil-Mata, S., Ferreira, A., Riera-Serra, P., Bognanni, A., Duarte, V. H., Viegas, H., Pereira, A. M., Ferreira-da-Silva, R., Ferreira-Cardoso, H., Marques-Cruz, M., Castro-Teles, J., Campos-Lopes, M., Teixeira-Ferreira, A., Lourenço-Silva, N., Boechat, J. L., Borowiack, E., Sadowska, E., Costa, R. A., …, & ARIA 2024-2025 Guideline Panel (2026). Efficacy and Safety of Oral Antihistamines for Allergic Rhinitis: Network Meta-Analysis. The Journal of Allergy and Clinical Immunology: In Practice. https://doi.org/10.1016/j.jaip.2025.12.034
Vancouver
Vieira RJ, Gil-Mata S, Ferreira A, Riera-Serra P, Bognanni A, Duarte VH, et al. Efficacy and Safety of Oral Antihistamines for Allergic Rhinitis: Network Meta-Analysis. The Journal of Allergy and Clinical Immunology: In Practice. 2026. doi:10.1016/j.jaip.2025.12.034
BibTeX
@article{Vieira2026,
author = {Vieira, Rafael José and Gil-Mata, Sara and Ferreira, André and Riera-Serra, Pau and Bognanni, Antonio and Duarte, Vítor Henrique and Viegas, Hugo and Pereira, Ana Margarida and Ferreira-da-Silva, Renato and Ferreira-Cardoso, Henrique and Marques-Cruz, Manuel and Castro-Teles, João and Campos-Lopes, Miguel and Teixeira-Ferreira, Ana and Lourenço-Silva, Nuno and Boechat, José Laerte and Borowiack, Ewa and Sadowska, Ewelina and Costa, Raquel Albuquerque and Perestrelo, Paula and Pereira, Marta Soares and Pereira-Macedo, Juliana and Ierodiakonou, Despo and Chu, Alexandro W L and Calvi, Izabela Pera and Torres, Maria Inês and Silva Ribeiro, Rita A and Thomander, Tuuli and Valiulis, Arunas and Cherrez-Ojeda, Ivan and Bedbrook, Anna and Klimek, Ludger and Yepes Nuñez, Juan Jose and Zuberbier, Torsten and Fonseca, João A and Schünemann, Holger J and Bousquet, Jean and Sousa-Pinto, Bernardo and ARIA 2024-2025 Guideline Panel, ARIA 2024-2025 Guideline Panel},
title = {Efficacy and Safety of Oral Antihistamines for Allergic Rhinitis: Network Meta-Analysis},
journal = {The Journal of Allergy and Clinical Immunology: In Practice},
year = {2026},
doi = {10.1016/j.jaip.2025.12.034}
}
EUVIMED